TET2 and acute myeloid leukemia: As shown in Figure 6G, mice receiving DMSO-treated Tet2-null leukemia cells developed aggressive AML with severe anemia (4 weeks after transplantation), whereas recipients of I-CBP112–treated Tet2-null leukemia cells showed improved survival with less severe anemia.